kaplan-meier survival analysis Search Results


90
CH Instruments kaplan–meier survival curves
Kaplan–Meier Survival Curves, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+survival+analysis/kaplan+meier+survival+analysis/pm25323232-87-0-17
Average 90 stars, based on 1 article reviews
kaplan–meier survival curves - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
MedCalc Software Ltd kaplan-meier survival analysis
Kaplan Meier Survival Analysis, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+survival+analysis/kaplan+meier+survival+analysis/10__1186_slash_s43057___020___00021___4-74-0-6
Average 90 stars, based on 1 article reviews
kaplan-meier survival analysis - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Rocha labs kaplanmeier
Kaplanmeier, supplied by Rocha labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+survival+analysis/kaplan+meier+survival+analysis/10__4025_slash_actascitechnol__v46i1__67282-67-0-29
Average 90 stars, based on 1 article reviews
kaplanmeier - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
MedCalc Software Ltd kaplan-meier curve and log-rank analyses
Kaplan Meier Curve And Log Rank Analyses, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+survival+analysis/log+rank+test+based+on+the+kaplan+meier+survival+analysis/pmc06612223-147-7-12
Average 90 stars, based on 1 article reviews
kaplan-meier curve and log-rank analyses - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Human Protein Atlas survival tcga kaplan-meier analyses
Survival Tcga Kaplan Meier Analyses, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+survival+analysis/kaplan+meier+survival+analysis/pm34973624-73-0-10
Average 90 stars, based on 1 article reviews
survival tcga kaplan-meier analyses - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
CH Instruments survival analysis a, kaplan-meier curves for survival, stratified by tertiles of gls
<t>A,</t> <t>Kaplan-Meier</t> curves for survival, stratified by tertiles of <t>GLS</t> (Chi2=85.16). B, Kaplan-Meier curves for survival, stratified by tertiles of LGE size (Chi2=8.01).
Survival Analysis A, Kaplan Meier Curves For Survival, Stratified By Tertiles Of Gls, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+survival+analysis/survival+analysis+a++kaplan+meier+curves+for+survival++stratified+by+tertiles+of+gls/pmc05494997-27-44-45
Average 90 stars, based on 1 article reviews
survival analysis a, kaplan-meier curves for survival, stratified by tertiles of gls - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
MedCalc Software Ltd two-way anova and kaplan-meier survival analysis
<t>A,</t> <t>Kaplan-Meier</t> curves for survival, stratified by tertiles of <t>GLS</t> (Chi2=85.16). B, Kaplan-Meier curves for survival, stratified by tertiles of LGE size (Chi2=8.01).
Two Way Anova And Kaplan Meier Survival Analysis, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+survival+analysis/two+way+anova+and+kaplan+meier+survival+analysis+using/pmc03804319-212-11-18
Average 90 stars, based on 1 article reviews
two-way anova and kaplan-meier survival analysis - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Abbott Laboratories kaplan–meier survival analysis
<t>A,</t> <t>Kaplan-Meier</t> curves for survival, stratified by tertiles of <t>GLS</t> (Chi2=85.16). B, Kaplan-Meier curves for survival, stratified by tertiles of LGE size (Chi2=8.01).
Kaplan–Meier Survival Analysis, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+survival+analysis/kaplan+meier+survival+analysis/pm38108430-88-5-9
Average 90 stars, based on 1 article reviews
kaplan–meier survival analysis - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Human Protein Atlas rna and protein expression of isg15 and the kaplan–meier survival analysis
Elevated expression and prognostic signature of <t>ISG15</t> in human RCC. Gene expression of ISG15 is illustrated as transcript per million (TPM) in normal kidneys versus primary tumors in A general population. B Different races. C Different biological sexes. D Different cancer stages. E Different tumor grades. F Different RCC subtypes including clear cell type A (ccA) and B (ccB). Protein expression of ISG15 is demonstrated as immunohistochemistry (IHC) staining in G normal kidney (patient ID: 1993) versus H RCC tumor (patient ID: 1352). I Survival probabilities in patients with high versus low ISG15 gene expression in the general population, male and female. The detailed statistical analysis is described in Supplemental Table 1
Rna And Protein Expression Of Isg15 And The Kaplan–Meier Survival Analysis, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+survival+analysis/data+on+rna+and+protein+expression+of+isg15+and+the+kaplan+meier+survival+analysis/pmc10992556-128-7-16
Average 90 stars, based on 1 article reviews
rna and protein expression of isg15 and the kaplan–meier survival analysis - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
MedCalc Software Ltd kaplanmeier survival analysis medcalc version 12.2.1.0
Elevated expression and prognostic signature of <t>ISG15</t> in human RCC. Gene expression of ISG15 is illustrated as transcript per million (TPM) in normal kidneys versus primary tumors in A general population. B Different races. C Different biological sexes. D Different cancer stages. E Different tumor grades. F Different RCC subtypes including clear cell type A (ccA) and B (ccB). Protein expression of ISG15 is demonstrated as immunohistochemistry (IHC) staining in G normal kidney (patient ID: 1993) versus H RCC tumor (patient ID: 1352). I Survival probabilities in patients with high versus low ISG15 gene expression in the general population, male and female. The detailed statistical analysis is described in Supplemental Table 1
Kaplanmeier Survival Analysis Medcalc Version 12.2.1.0, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+survival+analysis/kaplanmeier+survival+analysis+medcalc+version+12+2+1+0/pm25795484-92-16-16
Average 90 stars, based on 1 article reviews
kaplanmeier survival analysis medcalc version 12.2.1.0 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
MedCalc Software Ltd survival curves analysis by kaplan-meier logrank test
Elevated expression and prognostic signature of <t>ISG15</t> in human RCC. Gene expression of ISG15 is illustrated as transcript per million (TPM) in normal kidneys versus primary tumors in A general population. B Different races. C Different biological sexes. D Different cancer stages. E Different tumor grades. F Different RCC subtypes including clear cell type A (ccA) and B (ccB). Protein expression of ISG15 is demonstrated as immunohistochemistry (IHC) staining in G normal kidney (patient ID: 1993) versus H RCC tumor (patient ID: 1352). I Survival probabilities in patients with high versus low ISG15 gene expression in the general population, male and female. The detailed statistical analysis is described in Supplemental Table 1
Survival Curves Analysis By Kaplan Meier Logrank Test, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+survival+analysis/survival+curves+analysis+by+kaplan+meier+logrank+test/pmc02744870-139-0-9
Average 90 stars, based on 1 article reviews
survival curves analysis by kaplan-meier logrank test - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Unigene kaplan-meier survival analysis
Elevated expression and prognostic signature of <t>ISG15</t> in human RCC. Gene expression of ISG15 is illustrated as transcript per million (TPM) in normal kidneys versus primary tumors in A general population. B Different races. C Different biological sexes. D Different cancer stages. E Different tumor grades. F Different RCC subtypes including clear cell type A (ccA) and B (ccB). Protein expression of ISG15 is demonstrated as immunohistochemistry (IHC) staining in G normal kidney (patient ID: 1993) versus H RCC tumor (patient ID: 1352). I Survival probabilities in patients with high versus low ISG15 gene expression in the general population, male and female. The detailed statistical analysis is described in Supplemental Table 1
Kaplan Meier Survival Analysis, supplied by Unigene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+survival+analysis/kaplan+meier+survival+analysis/10__1172_slash_jci200420032-151-1-43
Average 90 stars, based on 1 article reviews
kaplan-meier survival analysis - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


A, Kaplan-Meier curves for survival, stratified by tertiles of GLS (Chi2=85.16). B, Kaplan-Meier curves for survival, stratified by tertiles of LGE size (Chi2=8.01).

Journal: Circulation

Article Title: Association of Feature-Tracking Cardiac Magnetic Resonance Imaging Left Ventricular Global Longitudinal Strain with All Cause Mortality in Patients with Reduced Left Ventricular Ejection Fraction

doi: 10.1161/CIRCULATIONAHA.117.027740

Figure Lengend Snippet: A, Kaplan-Meier curves for survival, stratified by tertiles of GLS (Chi2=85.16). B, Kaplan-Meier curves for survival, stratified by tertiles of LGE size (Chi2=8.01).

Article Snippet: Likewise, EF demonstrated a significant univariable association with death (HR=0.97 per %; 95%CI 0.95–0.99; p=0.006). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure caption a7 caption a8 Survival analysis A, Kaplan-Meier curves for survival, stratified by tertiles of GLS (Chi 2 =85.16).

Techniques:

Elevated expression and prognostic signature of ISG15 in human RCC. Gene expression of ISG15 is illustrated as transcript per million (TPM) in normal kidneys versus primary tumors in A general population. B Different races. C Different biological sexes. D Different cancer stages. E Different tumor grades. F Different RCC subtypes including clear cell type A (ccA) and B (ccB). Protein expression of ISG15 is demonstrated as immunohistochemistry (IHC) staining in G normal kidney (patient ID: 1993) versus H RCC tumor (patient ID: 1352). I Survival probabilities in patients with high versus low ISG15 gene expression in the general population, male and female. The detailed statistical analysis is described in Supplemental Table 1

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma

doi: 10.1007/s00262-022-03352-9

Figure Lengend Snippet: Elevated expression and prognostic signature of ISG15 in human RCC. Gene expression of ISG15 is illustrated as transcript per million (TPM) in normal kidneys versus primary tumors in A general population. B Different races. C Different biological sexes. D Different cancer stages. E Different tumor grades. F Different RCC subtypes including clear cell type A (ccA) and B (ccB). Protein expression of ISG15 is demonstrated as immunohistochemistry (IHC) staining in G normal kidney (patient ID: 1993) versus H RCC tumor (patient ID: 1352). I Survival probabilities in patients with high versus low ISG15 gene expression in the general population, male and female. The detailed statistical analysis is described in Supplemental Table 1

Article Snippet: Data on RNA and protein expression of ISG15 and the Kaplan–Meier survival analysis were obtained from Human Protein Atlas ( https://www.proteinatlas.org/ ) and the Cancer Genome Atlas ( https://cancergenome.nih.gov/ ) and from the University of Alabama at Birmingham, Comprehensive Cancer Center (UALCAN) as previously published [ 19 ].

Techniques: Expressing, Gene Expression, Immunohistochemistry

Elevated expression of ISG15 in mouse RCC cell lines and tumors. A Relative mRNA and B Log2 gene expression of ISG15 in Renca cell line compared to that of 3T3. C Relative mRNA, D Log2 gene expression, and E protein expression of ISG15 in Renca tumors compared to that of normal kidneys in Balb/c mice. F Relative ISG15 mRNA expression in Renca after a 24-h stimulation with IFN-β (1000 units/µL). G Relative ISG15 mRNA expression in Renca after a 24-h treatment with anti-IFNAR2 antibody (1 µg/µL)

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma

doi: 10.1007/s00262-022-03352-9

Figure Lengend Snippet: Elevated expression of ISG15 in mouse RCC cell lines and tumors. A Relative mRNA and B Log2 gene expression of ISG15 in Renca cell line compared to that of 3T3. C Relative mRNA, D Log2 gene expression, and E protein expression of ISG15 in Renca tumors compared to that of normal kidneys in Balb/c mice. F Relative ISG15 mRNA expression in Renca after a 24-h stimulation with IFN-β (1000 units/µL). G Relative ISG15 mRNA expression in Renca after a 24-h treatment with anti-IFNAR2 antibody (1 µg/µL)

Article Snippet: Data on RNA and protein expression of ISG15 and the Kaplan–Meier survival analysis were obtained from Human Protein Atlas ( https://www.proteinatlas.org/ ) and the Cancer Genome Atlas ( https://cancergenome.nih.gov/ ) and from the University of Alabama at Birmingham, Comprehensive Cancer Center (UALCAN) as previously published [ 19 ].

Techniques: Expressing, Gene Expression

Therapeutic efficacy on subcutaneous RCC tumors after Lm-LLO-ISG15 vaccination. A Experimental schema. 1 × 106 Renca cells in 100 µL PBS were implanted s.c. into the right hind flank of male Balb/c mice. Control Lm or Lm-LLO-ISG15 were subsequently vaccinated i.p. on days 5 (when tumors were palpable), 12, and 19. Tumor volumes were measured every 2–3 days. B Tumor growth kinetics with mean tumor volume and standard deviation of each treatment group throughout the experiment. C Individual tumor growth kinetics of Control Lm treated mice. D Individual tumor growth kinetics of Lm-LLO-ISG15 injected mice. E Final tumor mass. Mice from experiment 3B were euthanized on day 23 and tumors were dissected and weighed. F Representative images of tumors collected from E

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma

doi: 10.1007/s00262-022-03352-9

Figure Lengend Snippet: Therapeutic efficacy on subcutaneous RCC tumors after Lm-LLO-ISG15 vaccination. A Experimental schema. 1 × 106 Renca cells in 100 µL PBS were implanted s.c. into the right hind flank of male Balb/c mice. Control Lm or Lm-LLO-ISG15 were subsequently vaccinated i.p. on days 5 (when tumors were palpable), 12, and 19. Tumor volumes were measured every 2–3 days. B Tumor growth kinetics with mean tumor volume and standard deviation of each treatment group throughout the experiment. C Individual tumor growth kinetics of Control Lm treated mice. D Individual tumor growth kinetics of Lm-LLO-ISG15 injected mice. E Final tumor mass. Mice from experiment 3B were euthanized on day 23 and tumors were dissected and weighed. F Representative images of tumors collected from E

Article Snippet: Data on RNA and protein expression of ISG15 and the Kaplan–Meier survival analysis were obtained from Human Protein Atlas ( https://www.proteinatlas.org/ ) and the Cancer Genome Atlas ( https://cancergenome.nih.gov/ ) and from the University of Alabama at Birmingham, Comprehensive Cancer Center (UALCAN) as previously published [ 19 ].

Techniques: Drug discovery, Control, Standard Deviation, Injection

Lm-LLO-ISG15 inflames RCC tumors and enhances the influx of immune cells. Tumors from experiment 3E were harvested, dissociated to single cells, and subjected to multi-color flow cytometry as described in section Materials and methods. Tumor-infiltrating immune cells were gated based on the gating strategy as presented in Supplementary Figure S3. A–E Frequencies of A Live CD4+. B Live CD4+CD62Llow. C Live CD4+IL2+. D Live CD4+IFN-γ+. E Live CD4+TNF-α+. F, G Distribution of multi-cytokine produced by live CD4+. H–L Frequencies of H live CD8+. I Live CD8+CD62Llow. J Live CD8+IL2+. K Live CD8+IFN-γ+. L Live CD8+TNF-α+. K Live CD8+IFN-γ+TNF-α+. L Live CD8+PD-1+. M, N Distribution of multi-cytokine produced by live CD8+. O–Q Mean fluorescent intensity (MFI) of PD-1 from O TCR-β+. P Live CD4+ and Q live CD8+. R–T Frequencies of R live macrophage. P live m-MDSC, and Q live n-MDSCs

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma

doi: 10.1007/s00262-022-03352-9

Figure Lengend Snippet: Lm-LLO-ISG15 inflames RCC tumors and enhances the influx of immune cells. Tumors from experiment 3E were harvested, dissociated to single cells, and subjected to multi-color flow cytometry as described in section Materials and methods. Tumor-infiltrating immune cells were gated based on the gating strategy as presented in Supplementary Figure S3. A–E Frequencies of A Live CD4+. B Live CD4+CD62Llow. C Live CD4+IL2+. D Live CD4+IFN-γ+. E Live CD4+TNF-α+. F, G Distribution of multi-cytokine produced by live CD4+. H–L Frequencies of H live CD8+. I Live CD8+CD62Llow. J Live CD8+IL2+. K Live CD8+IFN-γ+. L Live CD8+TNF-α+. K Live CD8+IFN-γ+TNF-α+. L Live CD8+PD-1+. M, N Distribution of multi-cytokine produced by live CD8+. O–Q Mean fluorescent intensity (MFI) of PD-1 from O TCR-β+. P Live CD4+ and Q live CD8+. R–T Frequencies of R live macrophage. P live m-MDSC, and Q live n-MDSCs

Article Snippet: Data on RNA and protein expression of ISG15 and the Kaplan–Meier survival analysis were obtained from Human Protein Atlas ( https://www.proteinatlas.org/ ) and the Cancer Genome Atlas ( https://cancergenome.nih.gov/ ) and from the University of Alabama at Birmingham, Comprehensive Cancer Center (UALCAN) as previously published [ 19 ].

Techniques: Flow Cytometry, Produced

Depletion of CD8+ T cells abrogates Lm-LLO-ISG15-induced anti-RCC therapeutic efficacy. A Experimental schema. Balb/c male mice were implanted s.c. with Renca tumor cells (1 × 106 cells in 100 µL PBS) on day 0. CD8+ T cells were depleted on days 2, 4, 7, 11, and 16 post-tumor implantations. B Tumor growth kinetics with mean tumor volume and standard deviation of each treatment group throughout the experiment. C–E Individual tumor growth kinetics of each treatment group throughout the experiment. D Kaplan–Meier survival curve. Mice from experiment 5B were followed for ill health and the survival curve was generated on the day each mouse reached its tumor burden limit, i.e., a maximum diameter of 15 mm

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma

doi: 10.1007/s00262-022-03352-9

Figure Lengend Snippet: Depletion of CD8+ T cells abrogates Lm-LLO-ISG15-induced anti-RCC therapeutic efficacy. A Experimental schema. Balb/c male mice were implanted s.c. with Renca tumor cells (1 × 106 cells in 100 µL PBS) on day 0. CD8+ T cells were depleted on days 2, 4, 7, 11, and 16 post-tumor implantations. B Tumor growth kinetics with mean tumor volume and standard deviation of each treatment group throughout the experiment. C–E Individual tumor growth kinetics of each treatment group throughout the experiment. D Kaplan–Meier survival curve. Mice from experiment 5B were followed for ill health and the survival curve was generated on the day each mouse reached its tumor burden limit, i.e., a maximum diameter of 15 mm

Article Snippet: Data on RNA and protein expression of ISG15 and the Kaplan–Meier survival analysis were obtained from Human Protein Atlas ( https://www.proteinatlas.org/ ) and the Cancer Genome Atlas ( https://cancergenome.nih.gov/ ) and from the University of Alabama at Birmingham, Comprehensive Cancer Center (UALCAN) as previously published [ 19 ].

Techniques: Drug discovery, Standard Deviation, Generated

Therapeutic efficacy on orthotopic RCC tumors after Lm-LLO-ISG15 vaccination. A Experimental schema. 5 × 104 Renca-Luc cells in 50 µL PBS were implanted intra-renal into the left kidney of male Balb/c mice. Control Lm or Lm-LLO-ISG15 were subsequently vaccinated i.p. on days 3, 10, and 17. B Tumor growth kinetics with mean total influx was plotted as described in section Materials and methods. C Final tumor mass. Mice from experiment 6B were euthanized on day 20 and tumors were dissected and weighed. D A total number of lung surface metastatic nodules were counted with a stereo microscope. Mice from experiment 6B were euthanized on day 20 and lungs were fixed in Bouin's fixative solution and imaged at 24 h post-fixation. E Representative images of total influx collected from 6B. F Representative images of tumors (upper panel) and lungs (lower panel) collected from 6B

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma

doi: 10.1007/s00262-022-03352-9

Figure Lengend Snippet: Therapeutic efficacy on orthotopic RCC tumors after Lm-LLO-ISG15 vaccination. A Experimental schema. 5 × 104 Renca-Luc cells in 50 µL PBS were implanted intra-renal into the left kidney of male Balb/c mice. Control Lm or Lm-LLO-ISG15 were subsequently vaccinated i.p. on days 3, 10, and 17. B Tumor growth kinetics with mean total influx was plotted as described in section Materials and methods. C Final tumor mass. Mice from experiment 6B were euthanized on day 20 and tumors were dissected and weighed. D A total number of lung surface metastatic nodules were counted with a stereo microscope. Mice from experiment 6B were euthanized on day 20 and lungs were fixed in Bouin's fixative solution and imaged at 24 h post-fixation. E Representative images of total influx collected from 6B. F Representative images of tumors (upper panel) and lungs (lower panel) collected from 6B

Article Snippet: Data on RNA and protein expression of ISG15 and the Kaplan–Meier survival analysis were obtained from Human Protein Atlas ( https://www.proteinatlas.org/ ) and the Cancer Genome Atlas ( https://cancergenome.nih.gov/ ) and from the University of Alabama at Birmingham, Comprehensive Cancer Center (UALCAN) as previously published [ 19 ].

Techniques: Drug discovery, Control, Microscopy

The anti-tumor efficacy of Lm-LLO-ISG15 is comparable to that of the current standard of care. A Experimental schema. Balb/c male mice were implanted s.c. with Renca tumor cells (1 × 106 cells in 100 µL PBS) on day 0. PBS, anti-PD-1 (10 mg/kg), or Lm-LLO-ISG15 (2 × 108 CFU) were subsequently treated i.p. on day 5, 12, and 19. B Tumor growth kinetics with mean tumor volume and standard deviation of each treatment group throughout the experiment. C Kaplan–Meier survival curve. Mice from experiment 7B were followed for ill health and the survival curve was generated on the day each mouse reached its tumor burden limit, i.e., a maximum diameter of 15 mm. D Experimental schema. Balb/c male mice were implanted s.c. with Renca tumor cells (1 × 106 cells in 100 µL PBS) on day 0. Sunitinib (20 mg/kg, oral gavage daily from day 12 to 19), or Lm-LLO-ISG15 (2 × 108 CFU, i.p. on days 5, 12, and 19) were subsequently treated with appropriate controls in the mock group. E Tumor growth kinetics with mean tumor volume and standard deviation of each treatment group throughout the experiment. F Kaplan–Meier survival curve. Mice from experiment 7E were followed for ill health and the survival curve was generated on the day each mouse reached its tumor burden limit, i.e., a maximum diameter of 15 mm

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma

doi: 10.1007/s00262-022-03352-9

Figure Lengend Snippet: The anti-tumor efficacy of Lm-LLO-ISG15 is comparable to that of the current standard of care. A Experimental schema. Balb/c male mice were implanted s.c. with Renca tumor cells (1 × 106 cells in 100 µL PBS) on day 0. PBS, anti-PD-1 (10 mg/kg), or Lm-LLO-ISG15 (2 × 108 CFU) were subsequently treated i.p. on day 5, 12, and 19. B Tumor growth kinetics with mean tumor volume and standard deviation of each treatment group throughout the experiment. C Kaplan–Meier survival curve. Mice from experiment 7B were followed for ill health and the survival curve was generated on the day each mouse reached its tumor burden limit, i.e., a maximum diameter of 15 mm. D Experimental schema. Balb/c male mice were implanted s.c. with Renca tumor cells (1 × 106 cells in 100 µL PBS) on day 0. Sunitinib (20 mg/kg, oral gavage daily from day 12 to 19), or Lm-LLO-ISG15 (2 × 108 CFU, i.p. on days 5, 12, and 19) were subsequently treated with appropriate controls in the mock group. E Tumor growth kinetics with mean tumor volume and standard deviation of each treatment group throughout the experiment. F Kaplan–Meier survival curve. Mice from experiment 7E were followed for ill health and the survival curve was generated on the day each mouse reached its tumor burden limit, i.e., a maximum diameter of 15 mm

Article Snippet: Data on RNA and protein expression of ISG15 and the Kaplan–Meier survival analysis were obtained from Human Protein Atlas ( https://www.proteinatlas.org/ ) and the Cancer Genome Atlas ( https://cancergenome.nih.gov/ ) and from the University of Alabama at Birmingham, Comprehensive Cancer Center (UALCAN) as previously published [ 19 ].

Techniques: Standard Deviation, Generated